PetMed Express (PETS) Q4 2024 earnings summary

Executive summary

• Leadership transition with a new CEO and key executive hires to drive transformation and growth.

• Net sales rose 6.6% year-over-year to $66.5M in Q4, driven by PetCareRx acquisition, offset by legacy sales decline.

• Strategic focus on consolidating brands, enhancing technology, and improving customer experience.

• Emphasis on customer-centricity, operational efficiency, and leveraging partnerships for growth.

• Results impacted by macro environment, industry dynamics, and operational disruptions from new system implementations.

Financial highlights

• Q4 FY2024 sales reached $66.5 million, up 6.6% year-over-year, driven by the PetCareRx acquisition.

• Q4 gross profit was $18.2M, up from $17.4M year-over-year; gross margin was 27.3%, down from 27.9% year-over-year.

• Adjusted EBITDA was $0.5 million, down from $3.6 million in the prior year quarter; FY2024 Adjusted EBITDA was $8.2M, down from $19.8M.

• Net loss for Q4 was $5 million ($0.25 per diluted share), compared to a $0.2 million loss last year; FY2024 net loss was $7.5M versus net income of $5.1M in FY2023.

• Cash and cash equivalents at year-end were $55.3M, down from $104.1M, reflecting acquisition and dividend payments.

Outlook and guidance

• FY2025 priorities include driving growth, improving profitability, and increasing customer satisfaction metrics.

• Focus on top-line growth through technology, marketing, and operational improvements.

• Continued investment in digital transformation, AI, and automation to drive efficiency.

• Ongoing cost reduction and synergy realization from brand consolidation.

• Priority on customer acquisition, retention, and expanding recurring revenue streams.